March 26, 2014 -- Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCE, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial lung infections.
http://ift.tt/1oosC4A?
http://ift.tt/1oosC4A?
No comments:
Post a Comment